Trinity Biotech Secures Significant Orders for HIV Tests and Announces Q1 2026 Financial Results

Trinity Biotech plc has secured additional orders for over 2 million units of its TrinScreen™ HIV test, which are expected to contribute significantly to the company’s revenue and profitability targets for 2026. The orders reflect a strong demand for rapid HIV diagnostics following disruptions in 2025. The company also published its Q1 2026 financial results, reporting revenue in line with prior guidance and significant gross margin improvements. The additional orders and ongoing transformation plan are part of the company’s strategy to enhance manufacturing efficiency and scalability.